STAT3 and lung cancer: Shikonin could also enhance the antitumor effect of gefitinib in EGFR wild-type lung cancer via inhibition of PKM2/stat3/cyclinD1 signaling (Tang et al. 2018), and inhibit migration and invasion of lung cancer cells via inhibition of c-Met mediated EMT (Hsieh et al. 2017).